Secondary Polycythemia in Hepatocellular Carcinoma: Treat or No Treat

Poernomo Budi Setiawan, Ummi Maimunah, Nenci Siagian
Division of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine Universitas Airlangga/Dr Soetomo General Hospital, Surabaya

Corresponding author:
Ummi Maimunah. Division of Gastroentero-hepatology, Department of Internal Medicine, Dr. Soetomo General Hospital. Jl. Mayjend Prof Dr. Moestopo No. 6-8 Surabaya Indonesia. Phone +62-31-5501614; facsimile: +62-31-5023865. E-mail: ummima@gmail.com

ABSTRACT

A 45-year man with a chronic hepatitis B virus (HBV) infection, elevated alphafetoprotein (AFP) 628ng/dL and Abdominal CT-scan features of Hepatocellular Carcinoma was admitted with polycythemia condition. Polycythemia was because of hepatocellular carcinoma (HCC) as a paraneoplastic syndrome. Based on diagnosis criteria of HCC by Indonesian Association for the Study of the Liver 2017, the patient was diagnosed with HCC Barcelona clinic liver cancer (BCLC) B and was treated with trans arterial chemotherapy and embolization (TACE) with mixed doxorubicin. Aspirin 80mg once daily was given to patient to prevent thrombosis event. One month later after TACE, haemoglobin and hematocrit didn’t improve. Then 4 months later the patient died of cardiovascular event in the last admission at district hospital.

Keywords: hepatocellular carcinoma (HCC), polycythemia, trans arterial chemotherapy and embolization (TACE)

INTRODUCTION

Hepatocellular carcinoma (HCC) is a malignancy that arises from hepatocyte. HCC is the sixth most common cancer worldwide and the third most common cause of death from cancer. Approximately three-fourth of cases occur in Asian countries because of a high prevalence of chronic infection with HBV. HCC is undoubtedly a great health threat in Asian region.
Polycythemia or erythrocytosis is a well-known paraneoplastic phenomenon in patients with HCC with incidence about 3-12%, but its pathogenesis remains uncertain. Recently, it has been reported that HCC cells are responsible for the production of erythropoietin (EPO), which leads to polycythemia in HCC patients. Polycythemia as well as the others paraneoplastic syndromes play a significant role in the progress of HCC and lead to poor prognosis in patient HCC especially in increasing the risk of thrombosis event due to hyperviscosity in patient HCC. The guideline of treatment of secondary polycythemia in HCC is not established yet.

**CASE ILLUSTRATION**

A 45-year man with history of hepatitis B admitted to our health centre due to upper right abdominal pain progressively since 4 months ago and headache intermittently since 2 months ago. On admission laboratory analysis showed haemoglobin 20.4g/dL, haematocrit 65.4% and elevated alphafetoprotein (AFP) 628 ng/dL. The abdominal ultrasound which was taken 2 month before admission showed HCC and the chest x-ray showed normal cardiac and pulmo.

The abdomen MSCT with contrast which was performed on admission revealing enhancing solid lesion +/- 12.0x12.9x13.2 cm at segment V, VI, VII, VIII, seeded by right a. hepatica with early wash pattern at artery phase, early wash out pattern at venous phase and delay phase without thrombus or fistula, satellite nodul at segment II (HCC). In order to investigate a polycythemia an examination of erythropoietin (EPO) serum level was conducted revealing higher than normal 280mU/mL (4.1-19.5 mU/mL). The abdominal ultrasound which was taken 2 month before admission showed HCC and the chest x-ray showed normal cardiac and pulmo.

The abdomen MSCT with contrast which was performed on admission revealing enhancing solid lesion +/- 12.0x12.9x13.2 cm at segment V, VI, VII, VIII, seeded by right a. hepatica with early wash pattern at artery phase, early wash out pattern at venous phase and delay phase without thrombus or fistula, satellite nodul at segment II (HCC). In order to investigate a polycythemia an examination of erythropoietin (EPO) serum level was conducted revealing higher than normal 280mU/mL (4.1-19.5 mU/mL). This value confirmed the secondary polycythemia due to HCC. Trans arterial chemotheraphy and embolization (TACE) with mixed doxorubicin 50mg was performed as a recommended treatment of HCC and low dose aspirin 80mg was given as a prophylaxis of thrombotic risk due to polycythemia in this case. 1 month later after TACE and during low dose aspirin treatment, the haemoglobin and haemotocrite didn’t improve and 4 months later the patient died of cardiovascular event in the last admission at district hospital.

**DISCUSSION**

HCC is a primary cancer arising from hepatocytes in predominantly cirrhotic liver (70-90%) but it may not have cirrhosis before developing HCC, especially hep.B virus (30%). Men are generally more susceptible than women (2:1). Upper right quadrant abdominal pain and abdominal mass are common clinical manifestations of HCC. The positive of hepatitis virus marker, elevated alphafetoprotein (AFP) > 400ng/dL and HCC features by abdominal ultrasound/CT scan can confirm the diagnosis of HCC based on diagnostic criteria by the Indonesia’s liver researcher association 2017. The therapy is based on the stadium that consists of size, number of nodule, performance score and Child-pugh score.

Polycythemia or erythrocytosis is a blood disorder characterised by elevated haemoglobin (Hb) more than 18.5 g/dL (man)/ 16.5 g/dL (woman) or elevated haemotocrit (Ht) more than 52% (man)/48% (woman) (Keohane). In general polycythemia is divided into two main group (1) Absolute polycythemia which includes primary polycythemia (polycythemia vera, Epo-receptor mutation, etc) and secondary polycythemia due to tumor-associated polycythemia (HCC, renal tumor, uterine myoma, etc) and hypoxia-associated polycythemia (congenital heart disease, chronic obstruction pulmonary disease, asthma, etc); (2) Relative polycythemia due to loss volume plasma, dehidration, etc. Patients are generally asymptomatic, but the symptoms they may experience are related to ischemia from hyperviscosity and thrombosis due to increased red blood mass. General symptoms may include fatigue, weakness and dyspnea and others signs and symptoms include hepatosplenomegaly, headache, vertigo and tinnitus.

Patients with HCC that manifests paraneoplastic syndromes such as hypoglycemia, hypercholesterolemia and polycythemia usually has a larger tumor volume and high serum alpha-fetoprotein. Hwang et al. reported 20 (2.5%) of 792 chinese HCC patients presented with polycythemia then they found that 19 patients had either bi-lobar tumor involvement or a large tumor mass (50% whole liver) confined to one lobe of the liver. The pathogenesis of polycythemia in HCC is still unclear. Ke, et al, reported there is an underlying link between mitochondrial function and hypoxia inducible factor (HIF) alpha signaling, revealing a mechanism of polycythemia in HCC. Lack of alpha-ketoglutarate and prophyldehydroxilase makes HIF stable and induce over production of EPO then. EPO always binds to EPO receptor (EPOR) before transforms and activates the signaling of JAK-2 tranduction cascade that induce proliferation, stabilisation and differentiation of red blood cell. Thus, the new treatment using soluble EPO receptor to block EPO signaling.
The is a well defined association between polycythemia, rise in blood viscosity and the risk of thrombosis. The 34 year follow-up of the framingham cohort reported an association between being in the group with the highest packed red cell volume (five groups in total) and the risk of cardiovascular mortality and morbidity was 1.6 (p = 0.0018) for women and 1.29 (p = 0.019) for men aged 35-64 years who were in this group. Phlebotomy is an effective treatment modality for lowering hematocrit value in patients PV and secondary polycythemia but target hematocrit (<45%) was not achieved after a single phlebotomy. However, there is no study recommends routine phlebotomy for secondary polycythemia in HCC. It may because repeated phlebotomies could cause iron deficiency with microcytic erythrocytes that can actually increase rather than decrease blood viscosity and somehow induce erythrocytosis due to compensatory effect. In healthy men, a single 500-mL whole-blood donation results in a substantial loss of heme iron (i.e., 200–250 mg) and decreases serum ferritin levels by 44%. Thus, phlebotomy without a proper monitoring of blood viscosity can potentially accentuate rather than decrease the risk of a cardiovascular or cerebrovascular accident. Recently the datas showed therapeutic erythrocytapheresis (TEA) was clearly superior to traditional phlebotomy in terms of prolonging the period between one treatment and another, independent of the type of erythrocytosis and of the treatment group. For example, for the patients undergoing only phlebotomy, the treatment time interval was 51.66 ± 29.8 days, whereas for TEA patients it was 139 ± 49.5 (p < 0.001).

Low dose aspirin (80-100mg/day) is effective for prevention of arterial vascular events and for the primary prevention of venous thromboembolism. In 2014, aspirin was demonstrated by the European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) placebo-controlled randomized clinical trial, showing that low-dose aspirin can safely prevent thrombotic complications in patients with PV who have no contraindication to such treatment. Currently, hydroxyurea (HU) is recommended in PV patients who are at high risk of thrombosis, progressive disease, or in those who cannot tolerate frequent therapeutic phlebotomies. Based on results of a phase II study of The Polycythemia Vera Study Group (PVSG) trial, Hydroxyurea (HU), alone or in association with phlebotomy, was found efficacious and safe and is currently considered the first-line therapy in PV patients, but it has never been entered in controlled trials of adequate size and duration to assess its long-term safety.

The case described here demonstrates a palliative treatment such as TACE didn’t improve the polycythemia in HCC BCLC B. Low-dose aspirin was required to prevent the thrombotic event as long as the hematocrit >45%. Therapeutic phlebotomy should be considered in emergency case when the patient shows signs and symptoms of thrombosis. In the last admission at district hospital the patient had symptoms of thrombotic unfortunately phlebotomy couldn’t be done because of limitation source.

REFERENCES

1. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74.
2. Ke S, Chen S, Dong Z, Hong CS, Zhang Q, Tang L, et al. Erythrocytosis in hepatocellular carcinoma portends poor prognosis by respiratory dysfunction secondary to mitochondrial DNA mutations. Hepatology 2017;65:134-51.
3. Gagnon, R. D. & Kannel, B. W. Hematocrit and the Risk of Cardiovascular Disease-The Framingham Study: A 34-year follow-up. American Heart Journal 1994;674-82.
4. Qu Q, Wang S, Chen S, Zhou L, Ja R. Prognostic role and significance of paraneoplastic syndromes in hepatocellular carcinoma. Am Surg 2014;80:191-6.
5. Bisceglie AM, Befeler AS. Hepatic tumor and cysts. In: M, F. (ed.) Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, 10th ed. Philadelphia: Elsevier Inc. 2015.p. 63-61.
6. Drug Information and Reference: PPHI 2017. konsensus nasional penatalaksanaan karsinoma sel hati, perhimpunan peneliti hati indonesia.
7. Keohane C, McMullin FM, Harrison C. The diagnosis and management of erythrocytosis. BMJ 2013;x:f6667.
8. ADAMSON WJ, LONDO LD, ANEMIA AND POLYCYTHEMIA. In: Kasper DL, ed. Harrison’s Principles of Internal Medicine, 19th ed. New York: McGraw Hill Education; 2015.p. 393-4.
9. Prchal, TJ. Primary and Secondary Erythrocytosis. Chapter 57. In: Kaushansky K, Lichtman MA, Prchal JT, et al, eds Williams Hematology, 9th ed. New York, NY: McGraw Hill Medical. 2015.
10. Tefferi A. Diagnostic approach to the patient with polycythemia. UpToDate 2018.
11. Luo JC, Hwang SJ, Wu JC, Lai CR, Li CP, Chang FY, Chiang JH, Lui WY, Chu CW, Lee SD. Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes. Hepatogastroenterology 2002;49:1315-9
12. Chang PE, Ong WC, Lui HF; Tan CK. Epidemiology and prognosis of paraneoplastic syndromes in hepatocellular carcinoma. ISRN Oncol 2013:684026.
13. Kew CM. Paraneoplastic phenomena in patients with hepatocellular carcinoma. J Liver Res Disorder Ther 2016;29-12.
14. Huh UY, Kim JH, Kim BH, Nam KD, Jang JY, Kim NH, et al. The incidence and clinical significance of paraneoplastic syndromes in patients with hepatocellular carcinoma. Korean J Hepatol 2005;11:275-83.
Secondary Polycythemia in Hepatocellular Carcinoma: Treat or No Treat

15. Jokilehto, T. & Jaakkola, P. M. 2010. The role of HIF prolyl hydroxylases in tumour growth. J Cell Mol Med 2010;14:758-70.

16. Pearson TC, Weatherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative Polycythemia. Lancet 1978;2:1219-22.

17. Kong JH, Lee NS, Eom SH, Lee H, Han JY, Yoo H, et al. Assessment of effect of Phlebotomy in Patients with Polycythemia Vera and Secondary Polycythemia. Korean J Blood Transfus 2013;24:265-74.

18. Hyun JL, Kyung HS, Duyeal S, Sun ML. Optimal phlebotomy interval to change hematocrit levels in patients with polycythemia. Korean J Blood Transfus 2016;27:220-8.

19. Tso, C.S.A & Hua, P.S. Erythrocytosis in hepatocellular carcinoma: a compensatory phenomenon. British J Haematol 1974;28:147.

20. Holsworth ER, Weidman JJ, Sloop GD, St.Cyr AJ. Cardiovascular benefits of phlebotomy: relationship to changes in hemorheological variables. Perfusion 2013;29:x-x.

21. Vecchio S, Leonardo P, Musuraca V, D’Ettoris AR, Geremicca W. A comparison of the results obtained with traditional phlebotomy and with therapeutic erythrocytapheresis in patients with erythrocytosis. Blood Transfus 2007;5:20-23.

22. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose Aspirin in polycythemia vera. N Eng J Med 2004;350:114-24.

23. Ghirardi, A., Carobbio, A., Masciulli, A. & Barbui, T. Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data. Blood Cancer Journal 2018;8:5.